Navigation Links
Hard To Treat Diseases (HTDS.PK) 50,000 doses of Mevac A To Sri Lanka
Date:8/31/2009

SHENZHEN, China, Aug. 31 /PRNewswire-FirstCall/ - Hard to Treat Diseases (HTDS.PK) www.htdsmedical.com - is pleased to announce today that Mellow Hope, an operating subsidiary of HTDS, is providing another government tender. This one is for 50,000 doses of Mevac A in Sri Lanka. Mellow Hope maintains a good relationship with a local partner, who is one of the leading pharmaceutical companies in Sir Lanka.

Mr. Terry Yuan, CEO of HTDS, said "Although these are tenders they are worthwhile mentioning especially when our confidence is high that we will be awarded this tender. We are hoping to be in a position to release the results October 2009 for Sri Lanka. Just as we announced our Chile tender (see news Aug 07, 2009), we are pleased to announce that significant strides were made on that front as well. Because this is a significant deal (the largest single order the company will fulfill to date), these strides required my attendance in Chile this week to iron out any fine details which may remain outstanding. Regrettably due to the sudden required trip to Chile, I was unable due to scheduling to attend the Expo in Toronto Canada where HTDS' interests in Slavica Bio Chem and Mellow Hope were proudly exhibited by our Science correspondent for our shareholders, and other professionals that attended the event. Now, subsequent to the Expo we have received many inquiries where amongst other things, shareholders were concerned about certain "reports" that were being posted or circulating on the Internet that some individuals have "met with CEO of HTDS" and the prognoses for HTDS is not good, and other similar falsehoods. Again, I was unable due to scheduling to attend the Expo in Toronto, and no such conversation took place, nor is there any truth to it. I know that our investor relations company (Mina Mar Group) takes these matters quite seriously and takes legal action against these types of activities. We also ask our followers to review our "Get the Facts Right" corporate policy, and to rely only upon official company releases, and filings on Pink Sheets, and not those with hidden motives.

"We have recently re filed our Adequate Disclosure with pink sheets which is as current as it possibly can be. We have also heard back from Pink Sheets regarding our aspirations of obtaining the 'current issuer ranking'. Additional supporting documents and other clarifications will be filed this week to obtain this ranking however the substance and the content of our Adequate Disclosure remains the same, and we again remind our followers that only this document filed with pink Sheets and our official web sites are the most current and accurate sources of information."

The company intends to provide further updates on a timely basis.

Get the Facts Right. The issuer works hard to continue to keep our shareholders informed, and news is updated frequently via Press Releases, Pink Sheet filings (www.pinksheets.com), and updates to our websites. Other websites not sponsored, or recognized by the Company may provide misleading or disinformation to investors in order to manipulate trading patterns for a given stock. Always look for original content from trusted sources, rather than relying on 'excerpts' or discussion boards that may not give you the whole story. The Securities and Exchange Commission requires financial institutions or brokerage firms to provide their clients with documentation describing the risks of investing in penny stocks.

Safe Harbor Statement

Information in this news release may contain statements about future expectations, plans, prospects or performance of Hard To Treat Diseases Inc that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. Hard To Treat Diseases Inc cautions you that any forward-looking information provided by or on behalf of Hard To Treat Diseases Inc is not a guarantee of future performance. None of the information in this press release constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard To Treat Diseases Inc's actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard To Treat Diseases Inc's control. In addition to those discussed in Hard To Treat Diseases Inc's press releases, public filings, and statements by Hard To Treat Diseases Inc's management, including, but not limited to, Hard To Treat Diseases Inc's estimate of the sufficiency of its existing capital resources, Hard To Treat Diseases Inc's ability to raise additional capital to fund future operations, Hard To Treat Diseases Inc's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard To Treat Diseases Inc's capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard To Treat Diseases Inc does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.

CONTACT: For medical and scientific dialogue inquiry only, please contact medicalinfo@htdsmedical.com; For any corporate matters, please contact www.minamargroup.com/helpdesk IR dept (302) 357-9915


'/>"/>
SOURCE Hard to Treat Diseases
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Varian Medical Systems Adds RapidArc(R) and Image Guidance to New Low Energy Treatment Platform for Radiation Therapy in International Cancer Clinics
2. Solve Skin Conditions and Receive Hair Loss Treatment from Home with New Line of Medical Devices Called Dermaray
3. Waismann Method Offers Safe Treatment for Dependency to Benzodiazepines
4. New tool to predict the risk of death in COPD may help physicians to individualize treatment
5. Hard To Treat Diseases (HTDS.PK) - 46,000 India Doses of Hepatitis A
6. Promising Cancer Research Treatment Breakthrough Seeks Funding for Corroboration of Results
7. Stem Cell Treatment Breakthrough
8. Los Angeles Clinic (laserandveinclinic.com) Offers the Latest Laser Skin Rejuvenation Treatments
9. Treating COPD Early Improves Outcomes
10. More Than Four Out of Five Dentists Surveyed Reveal That Texting During Dental Treatment a Common Problem
11. NeuroVasx Receives Canadian Approval for cPAX Aneurysm Treatment System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... City, FL (PRWEB) , ... February 11, 2016 ... ... announced the commencement of a master charity program created to assist the people ... 60 days, working closely with nonprofit organizations and community leaders. Their hope is ...
(Date:2/11/2016)... ... February 11, 2016 , ... Duterte Insurance Group, serving ... introduces a new charity campaign to raise funds for Ronald McDonald House Charities. ... https://donate.rmhc.org/ . , Ronald McDonald House (RMH) is an internationally renowned nonprofit ...
(Date:2/11/2016)... ... ... Be Well Medical Group (Be Well) is pleased to announce ... South Columbus St, Suite 201, Alexandria, VA. Be Well Medical Group is a concierge ... of their homes, offices or at the practices’ local office. It is also one ...
(Date:2/11/2016)... ... February 11, 2016 , ... Food Labeling for American ... and wellness best practices in the past couple of decades, and food manufacturers ... Heart Month, which acts as an exceptional opportunity to revise food labels and ...
(Date:2/10/2016)... ... 10, 2016 , ... President Obama’s budget proposal yesterday enables ... medical services via telehealth, estimated to generate more than $160 million in savings ... many years. Although there is more to be done, this represents an ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... Breast Cancer Therapeutics in Asia-Pacific Markets to 2021 ... breast cancer market will experience considerable expansion from $1.9 billion ... Annual Growth Rate (CAGR) of 8.5%. --> Breast ... that the Asia-Pacific (APAC) breast cancer ... to $3.4 billion by 2021, at a Compound Annual Growth ...
(Date:2/11/2016)... PLAD, Inc. (OTC Pink: PLAD) is pleased to announce ... company targets, are adding key personnel to their national ... United States Patent and Trademark Office for the characters ... of PLAD, Inc.  In January, PLAD established their presence ... with two new customers, Cumberland Goodwill EMS and Meadville ...
(Date:2/11/2016)... 2016  M3 Biotechnology Inc., spurred by a major "team investment" by Bruce Montgomery , ... an oversubscribed Series A-Round, according to CEO Leen Kawas , PhD. ... ... ... Kawas said the ...
Breaking Medicine Technology: